ReviewInternational journal of molecular medicine2026
Importance of B cells (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Review
- Temporal shifts in adaptive immunity drive HIV-associated cryptococcal IRIS: mechanisms, models, and therapeutic opportunities.NeuroImmune pharmacology and therapeutics · 2026Article
- Modulation of the tumor microenvironment by incretins and glucagon: Metabolic and immune mechanisms (Review).Experimental and therapeutic medicine · 2026Review
- Article
- B-Cell Depletion as Evidence for Shared Neuroimmune Pathways in Combined Central and Peripheral Demyelination: A Case Report and Literature Review.International journal of molecular sciences · 2026Review
- Roles of immune cell metabolism in rheumatoid arthritis.Frontiers in immunology · 2026Review
- Mechanistic remodeling and immunoregulatory functions of the B cell-humoral immunity axis in inflammatory bowel disease.Frontiers in immunology · 2026Review
- B-1a cells mitigate radiation injury by protecting intestinal barrier integrity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a key component of the immune system, B cells primarily mediate humoral immunity via the synthesis and secretion of antibodies. In addition, B cells contribute to immune responses via antigen presentation and cytokine secretion. B cell‑targeted therapy has potential for the treatment of autoimmune diseases. However, current B cell‑targeted therapies have limited efficacy when used as monotherapies in clinical settings. In an aim to provide in‑depth understanding of this limitation, the present review discusses the developmental and differentiation pathways of B cells and the mechanisms by which various B cell subsets participate in immune responses, as well as randomized controlled trials on B cell‑targeted therapies conducted on lupus nephritis, an autoimmune disease with a notable inflammatory response. The clinical benefits of these therapies remain modest. This suggests that while B cells may serve a pathogenic role, existing therapies fail to address the fundamental mechanisms underlying disease progression. Targeting the interactions between B and T cells, particularly by inhibiting B cell‑mediated antigen presentation, may represent a promising novel direction for B cell‑targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.